To evaluate the in vitro antimicrobial activities of biapenem, arbekacin, and cefminox against different gram-negative bacterial isolates in China, a total of 100 non-duplicated Escherichia coli, 100 Acinetobacter baumannii, 100 Pseudomonas aeruginosa, and 99 Klebsiella pneumoniae isolates were collected from 6 teaching hospitals in China in 2012. The minimal inhibitory concentrations (MICs) of biapenem, arbekacin, cefminox and 13 other antibiotics were determined by the broth microdilution method. The carbapenems (biapenem, meropenem, and imipenem) exhibited high antimicrobial activity against E. coli (98z) and K. pneumoniae (95z), followed by colistin and amikacin. The MIC 50 and MIC 90 of biapenem against E. coli were 0.06 mg/L and 0.25 mg/L, respectively. For K. pneumoniae, the MIC 50 and MIC 90 of biapenem were 0.25 mg/L and 1.0 mg/L, respectively. The MIC 50 and MIC 90 of cefminox against E. coli were 1.0 mg/L and 4.0 mg/L, respectively. The resistance rates of A. baumannii to most of the antibiotics were more than 50z, except for colistin. Amikacin was the most active antibiotic against P. aeruginosa (97z), followed by colistin (93z). The MIC 50 and MIC 90 of arbekacin against P. aeruginosa were 2.0 mg/L and 8.0 mg/L, respectively. In conclusion, carbapenems, colistin, amikacin, and arbekacin exhibited high antimicrobial activities against gramnegative bacteria, except A. baumannii.
INTRODUCTION
At present, multidrug-resistant (MDR) gram-negative bacteria pose a great challenge to clinicians with regard to the choice of appropriate antimicrobial therapy, especially the initial empirical treatment. MDR strains have been associated with higher mortality, prolonged hospital stays, and increased medical costs as compared to susceptible strains (1) .
Carbapenems are often the last choice of drugs for therapy of infectious caused by MDR strains. Biapenem is a parenteral carbapenem antibacterial agent that was launched in Japan in 2001 and has a broad spectrum of activity against gram-negative, gram-positive, and anaerobic bacteria (2) . Aminoglycoside antibiotics exhibit in vitro activity against a wide variety of clinically important gram-negative bacilli, as well as Staphylococcus aureus (S. aureus ) and some streptococci. Arbekacin is an aminoglycoside licensed for use as an anti-methicillin-resistant S. aureus (MRSA) drug in Japan. It binds to the bacterial 30S ribosomal subunit, thereby inhibiting protein synthesis (3) . Cefminox is a semisynthetic cephamycin possessing a broad spectrum of antibacterial activity against gram-positive, gram-negative, and anaerobic bacteria, except Enterococcus faecalis and Pseudomonas aeruginosa (P. aeruginosa) (4) . Although several studies have described the antibacterial activity of biapenem, arbekacin, and cefminox against gram-negative bacteria in Asia (4-7), none have evaluated the in vitro antimicrobial activities of these antibiotics in China. In this study, 100 Escherichia coli (E. coli ), 100 Acinetobacter baumannii (A. baumannii), 100 P. aeruginosa, and 99 Klebsiella pneumonia (K. pneumonia) isolates were collected from 6 hospitals in China in 2012. The minimum inhibitory concentrations (MICs) of biapenem, arbekacin, cefminox and 13 other antibiotics were determined by the broth-microdilution method, to evaluate their in vitro antibacterial activity against gram-negative bacteria that commonly cause nosocomial infections.
MATERIALS AND METHODS
Bacterial isolates: A total of 100 E. coli, A. baumannii, and P. aeruginosa, and 99 K. pneumoniae nonduplicated isolates (Table 1) were collected from 6 teaching hospitals in China in 2012. The isolates were identified at a local laboratory, and their identify was re-confirmed at the central laboratory (Clinical Microbiology, Peking University People's Hospital) using colony morphology, routine biochemical tests, a 429 C growth test (for A. baumannii ), and/or VITEK System identification cards (bioMerieux, Hazelwood, MO, USA), as required. All isolates were stored at -809 C until MIC testing.
Antimicrobial susceptibility testing: The MICs for each antibiotic against the aforementioned bacteria were determined by the broth-microdilution method using designed MIC panels manufactured by the Eiken Chemical Co., Ltd. (Tokyo, Japan), according to Clinical and Laboratory Standards Institute (CLSI) guidelines (8) . The antimicrobials tested included biapenem, (9) . The CLSI extended-spectrum b-lactamases (ESBLs)-screening criteria (MIC 2 mg/L for ceftazidime, cefotaxime, ceftriaxone, and aztreonam) were applied to E. coli and K. pneumoniae. Two pairs of drug combinations, cefotaxime/cefotaxime-clavulanate and ceftazidime/ceftazidime-clavulanate, were used to confirm the production of ESBLs for suspicious isolates. Isolates were considered ESBL positive if the MIC of the antimicrobial drug with clavulanate was 3 two-fold lower that of the drug alone. E. coli ATCC 25922 and K. pneumonia ATCC 700603 were used as controls in the ESBL test.
Data analysis: For each isolate, every center recorded detailed information, including specimen type, collection date, and location type, and filled out standardized tables. All this information, as well as the MIC data, were analyzed using WHONET5.6 (WHO, Geneva) software at the central laboratory.
RESULTS

Specimen types:
Of the 100 non-duplicated E. coli isolates, 24z were recovered from blood, 17z from respiratory tract specimens, and 59z from urine. Of the 99 K. pneumoniae isolates, 38z were recovered from blood, 31z from respiratory tract specimens, and 31z from urine. Of the 100 A. baumannii isolates, 33z were recovered from blood, 61z from respiratory tract specimens, and 6z from urine. Of the 100 P. aeruginosa isolates, 40z were recovered from blood, 35z from respiratory tract specimens, and 25z from urine.
E. coli: Antimicrobial susceptibility data for E. coli, K. pneumoniae, A. baumannii, and P. aeruginosa are presented in Table 2 . Meropenem and imipenem were the most active agents against E. coli isolates (98z), followed by colistin (96z). ESBL phenotypes accounted for 55z of all E. coli isolates. For E. coli, the MIC 50 and MIC 90 were as follows: biapenem, 0.06 mg/L and 0.25 mg/L; meropenem, 0.06 mg/L for both; and imipenem, 0.125 mg/L and 0.25 mg/L, respectively.
The MIC 50 of imipenem against E. coli was 2-fold higher than that of biapenem and meropenem. The MIC 90 s of biapenem and imipenem against E. coli strains were 4-fold higher than that of meropenem. The MIC 50 and MIC 90 of cefminox against E. coli were 1.0 mg/L and 4.0 mg/L, respectively. The MIC 50 of arbekacin against E. coli was 4-fold lower than that of amikacin, and 32-fold lower than that of gentamicin. The MIC 90 of arbekacin against E. coli was 8 fold lower than that of gentamicin. For the 55 ESBL-producing E. coli strains, meropenem, imipenem, and colistin were the most active agents (96.4z), followed by amikacin (83.6z) and piperacillin/tazobactam (76.4z). The susceptibility rates of the remaining antibiotics were less than 40z.
For E. coli, 98z of isolates were inhibited by biapenem or meropenem MICs of 1.0 mg/L, and 98z of isolates were inhibited by an imipenem MIC of 0.5 mg/L. Ninety percent of E. coli isolates were inhibited by amikacin or arbekacin MICs of 16.0 mg/L; further, 89z of the isolates were inhibited by an arbekacin MIC of 8.0 mg/L, and 82z of the isolates were inhibited by an arbekacin MIC of 4.0 mg/L. However, only 34z of E. coli isolates were inhibited by a gentamicin MIC of 4.0 mg/L. Ninety-three percent and 96z of E. coli isolates were inhibited by cefminox MICs of 8.0 and 16.0 mg/L, respectively. Only 13z of the E. coli isolates were inhibited by a levofloxacin MIC of 2.0 mg/L, which is the susceptible breakpoint.
K. pneumonia: For the 99 K. pneumoniae strains, meropenem and imipenem were the most active agents against the isolates (95z), followed by colistin (95z). The ESBL phenotypes accounted for 45z of K. pneumoniae. For K. pneumoniae, the MIC 50 and MIC 90 for biapenem and imipenem were 0.25 mg/L and 1.0 mg/L, respectively, while those for meropenem were 0.06 mg/L and 0.125 mg/L, respectively. The MIC 50 of meropenem against K. pneumoniae was 4-fold lower than that of biapenem and imipenem. The MIC 90 of meropenem against K. pneumoniae was 8-fold lower than that of biapenem and imipenem. The MIC 50 and MIC 90 of cefminox against K. pneumoniae were 1.0 mg/L and 128.0 mg/L, respectively. The MIC 50 of arbekacin against K. pneumoniae was 2-fold lower than that of amikacin and 2-fold higher than that of gentamicin. The MIC 90 of arbekacin against K. pneumoniae was lower than that of amikacin and gentamicin. For the 45 ESBL-producing K. pneumoniae strains, meropenem and colistin were the most active agents (93z), followed by imipenem (91z), amikacin (84z), and piperacil- In vitro Antibacterial Activities of Biapenem lin/tazobactam (62z). The susceptibility rates of the remaining antibiotics were less than 50z. For K. pneumoniae, 94z and 95z of the isolates were inhibited by imipenem or biapenem MICs of 1.0 mg/L, and 95z of isolates were inhibited by a meropenem MIC of 0.5 mg/L. Eighty-three percent of K. pneumoniae isolates were inhibited by an amikacin MIC of 8.0 mg/L or an arbekacin MIC of 4.0 mg/L. However, only 56z of K. pneumoniae isolates were inhibited by a gentamicin MIC of 4.0 mg/L. Seventy percent and 75z of K. pneumoniae isolates were inhibited by cefminox MICs of 2.0 and 16.0 mg/L, respectively. Only 44z of K. pneumoniae isolates were inhibited by ceftriaxone or cefotaxime MICs of 1.0 mg/L, which is the susceptible breakpoint.
A. baumannii: Of the 100 A. baumannii strains, the susceptibility rates of A. baumannii to the all antibiotics, except colistin, were lower than 50z. The MIC 50 and MIC 90 of colistin for A. baumannii were 0.5 mg/L. P. aeruginosa: For the 100 P. aeruginosa strains, amikacin was the most active agent (95z). The second most-active agent against P. aeruginosa was colistin (93z). For P. aeruginosa, the MIC 50 s of arbekacin and gentamicin were 2-fold lower than that of amikacin. Further, the MIC 90 s of arbekacin and amikacin for P. aeruginosa was 4-fold lower than that of gentamicin. The MIC 50 of biapenem for P. aeruginosa was 2-fold lower than that of imipenem and meropenem. The MIC 90 for biapenem, imipenem, and meropenem was 16.0 mg/L.
For P. aeruginosa, 94z, 90z, and 87z of isolates were inhibited by arbekacin, amikacin, and gentamicin MICs of 8.0 mg/L, respectively. Further, 95z, 97z, and 89z of isolates were inhibited by arbekacin, amikacin, and gentamicin MICs of 16.0 mg/L, and 75z, 69z, and 65z of P. aeruginosa strains were inhibited by biapenem, meropenem, and imipenem MICs of 2.0 mg/L.
DISCUSSION
In this study, carbapenems (biapenem, meropenem, and imipenem) exhibited high antimicrobial activity against most of the E. coli and K. pneumonia isolates, followed by colistin, arbekacin, and amikacin. Since half of the E. coli and K. pneumonia isolates were ESBL producers, ceftriaxone and cefotaxime showed high resistance rates. Except for the carbapenems, colistin, amikacin, and piperacillin/tazobactam, the resistance rates of ESBL-producing E. coli and K. pneumonia isolates to most of the tested antibiotics were high.
Biapenem has a broad spectrum of in vitro antibacterial activity against gram-negative (including blactamase-producing strains and P. aeruginosa ), grampositive, and anaerobic bacteria (10, 11) . A previous study demonstrated that biapenem is as effective and well tolerated as imipenem/cilastatin in the treatment of intermediate and severe bacterial infections (11) . A small number of carbapenem-resistant E. coli isolates have emerged in China (12, 13) . Our previous study showed that two resistance mechanisms involved in carbapenem-resistant enterobacteriaceae isolates included the production of carbapenemases and the loss or decreased expression of outer membrane proteins, in combination with the production of AmpC or ESBL enzymes (13) . Livermore and Mushtaq (14) reported that biapenem (RPX2003) in combination with the boronate b-lactamase inhibitor RPX7009 (Carbavance) could overcome most of the resistance caused by K. pneumoniae carbapenemases and other class A carbapenemases. Class B and D carbapenemases were not inhibited, but conferred less consistent resistance to biapenem than to other carbapenems (14) .
Arbekacin and amikacin were the second most-active agents against E. coli isolates. Arbekacin, which is a semi-synthetic aminoglycoside antibiotic, is active against both gram-positive and gram-negative bacteria and is not affected by the aminoglycoside-modifying enzymes produced by MRSA. It lyses E. coli by causing membrane damage and inhibits translation by binding to bacterial ribosomal subunits (15) . A previous study showed that the MIC 90 s of arbekacin for E. coli and Citrobacter freundii were 1.0 g/mL and 16.0 g/mL, respectively, which were 2-to 4 fold and 8-to 16-fold lower than those of amikacin and gentamicin, respectively (5). Therefore, most E. coli isolates were susceptible to arbekacin.
Cefminox was shown to exhibit high activity against ESBL-producing E. coli (16) , which is consistent with our current results. Cefminox has broad-spectrum antimicrobial activity and is therefore, it suitable for prophylaxis in surgical procedures, where a mixed infection may occur (17) .
Recently, pan-resistant A. baumannii, which are resistant to most antibiotics, except for colistin and tigecycline, has become one of the most important causes of nosocomial infections worldwide. Our current study showed that the resistance rates of A. baumannii to all antibiotics were more than 50z, except for colistin. Our previous study showed that A. baumannii has exhibited decreased susceptibilities to meropenem and imipenem (18) . The susceptibility of A. baumannii to meropenem reduced significantly, from 94.6z in 2003 to 60.7z in 2008, while its the susceptibility to imipenem reduced from 92.5z to 62.1z. The resistance rates of A. baumannii to meropenem and imipenem in this study were 53z and 52z, respectively. For pan-resistant A. baumannii, the use of new antibiotics should be explored, and at the same time, measure for strict prevention and control of nosocomial infections should be initiated to avoid outbreaks in hospitals.
P. aeruginosa is one of the most important pathogens causing hospital-acquired pneumonia, urinary tract infections, surgical site infections, and bacteremia. We found that the resistance rates of P. aeruginosa to most antibiotics were less than 30z. Our previous study showed that the susceptivility rate of P. aeruginosa to meropenem was relatively stable, increasing from 76.0z in 2003 to 86.2z in 2008, while its susceptibility to imipenem increased from 70.5z to 74.8z (18) . However, in the current study, the susceptibility rates of P. aeruginosa to meropenem and imipenem were 69z and 65z, respectively. The MIC 50 of biapenem for P. aeruginosa (0.5 mg/L) was lower than that of meropenem and imipenem (1.0 mg/L). Biapenem shows a good post-antibiotic effect, similar to imipenem, and has a high bactericidal activity against biofilm-forming Pseudomonas strains (19) and several efflux-system mutants (20) . Although the in vitro activity of biapenem against P. aeruginosa was similar to that of imipenem in most investigations, two studies have shown that biapenem was more active than imipenem (7, 21) . Another study indicated that a novel metallo-b-lactamase (MBL) inhibitor (ME1071) could potentiate the activity of ceftazidime and carbapenems (especially biapenem) against MBL-producing strains of P. aeruginosa (22) . Arbekacin and amikacin were the most active agents against P. aeruginosa isolates. The MIC 50 of arbekacin for P. aeruginosa (2.0 mg/L) was lower than that of amikacin (4.0 mg/L). Moreover, arbekacin has demonstrated efficacy against clinical isolates of P. aeruginosa (6) . A previous study indicated that aztreonam ＋ arbekacin was the most promising combination regimen against MDR P. aeruginosa strains (23) . Therefore, arbekacin can be considered a potential candidate for the future treatment of diseases caused by P. aeruginosa.
In summary, carbapenems (biapenem, meropenem, and imipenem) exhibited high antimicrobial activities against gram-negative bacteria, except for A. baumannii. Cefminox exhibited high activity against ESBLproducing E. coli. Isolates. Arbekacin and amikacin were the second most active agents against enterobacteriaceae isolates. Most antibiotics showed antimicrobial activity against P. aeruginosa, and amikacin was the most active agent. Pandrug-resistant A. baumannii has become one of the most important causes of nosocomial infections in China, and strict prevention and control measurements are required for such infections.
